Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axonics, Inc. - Common Stock (NQ:AXNX)

70.98 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axonics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
From RxSight, Inc.
Via GlobeNewswire
Axonics Reports Third Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
From Axonics, Inc.
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
 
Via Benzinga
Analyst Scoreboard: 5 Ratings For Axonics
 
Via Benzinga
Why Axonics Stock Soared Today
The medical device maker agreed to be acquired by Boston Scientific. 
Via The Motley Fool
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Second Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
7 Robotics Stocks That Could Grow Your Wealth
Explore robotics stocks with the potential to grow investors' wealth as the industry expands across various sectors. 
Via InvestorPlace
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
From Axonics, Inc.
Via Business Wire
Health Care Company Boston Scientific Announces Acquisition of Axonics
 
Via Benzinga
AXNX Stock Earnings: Axonics Misses EPS, Beats Revenue for Q1 2024
AXNX stock results show that Axonics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Axonics Reports First Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolization. Potential adverse effects include bowel ischemia, necessitating major... 
Via Benzinga
Axonics Stockholders Approve Merger Agreement with Boston Scientific
From Axonics, Inc.
Via Business Wire
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics Responds to ITC Action by Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Axonics, Inc.
Via Business Wire
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
From Kahn Swick & Foti, LLC
Via Business Wire
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Robinhood, Palo Alto Networks And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
10 Top Stocks With a Strong Buy Rating Right Now
Wall Street is highly bullish on these strong buy stocks, even as financial markets face an uncertain year. Here are the names to watch. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Crocs (CROX) Stock Up 20% Today?
Crocs stock is heading higher on Monday with heavy trading of CROX shares after the company posted a strong outlook for 2024! 
Via InvestorPlace
Why Is Axonics (AXNX) Stock Up 20% Today?
Axonics stock is rising higher on Monday as investors react to a $71 per share cash offer for AXNX stock from Boston Scientific. 
Via InvestorPlace
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $7 
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.